SIRT6 was recently shown to regulate metabolic reprogramming in cancer cells via metabolic signaling pathways decreasing the expression of glycolytic genes, including GLUT1 and HIF1-alpha and decreasing glucose uptake and lactate formation by cells. This evidence concerns the gene SLC2A1 and cancer.